ReviewNature reviews. Immunology2017
Immunogenic cell death in cancer and infectious disease.
Review in Nature reviews. Immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03965468 (A Multicentre Single Arm Phase II Trial Assessing the Efficacy of Immunotherapy, Chemotherapy and Stereotactic Radiotherapy to Metastases Followed by Definitive Surgery or Radiotherapy to the Primary Tumour, in Patients With Synchronous Oligo-metastatic Non-small Cell Lung Cancer), which is not on this map. Cited by 1,639 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicentre Single Arm Phase II Trial Assessing the Efficacy of Immunotherapy, Chemotherapy and Stereotactic Radiotherapy to Metastases Followed by Definitive Surgery or Radiotherapy to the Primary Tumour, in Patients With Synchronous Oligo-metastatic Non-small Cell Lung Cancer
Who cites it
1,639 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Pooled it
- Efficacy hierarchy and absolute survival benefit of first-line immunotherapy in advanced gastric cancer: a meta-analysis and pooled survival analysis.Frontiers in immunology · 2026Pooled it
- Immune checkpoint inhibitors plus chemotherapy for early-stage or locally -advanced triple-negative breast cancer: a systematic review and Bayesian network meta-analysis of randomized trials.Frontiers in oncology · 2026Pooled it
- The safety and efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a meta-analysis and systematic review.Frontiers in immunology · 2026Pooled it
- Efficacy and safety of neoadjuvant chemotherapy with immunotherapy versus chemotherapy alone in esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials.Frontiers in immunology · 2026Pooled it
- Nonlinear duration-efficacy association of neoadjuvant PD-1/PD-L1 blockade with chemoradiotherapy in pMMR/MSS locally advanced rectal cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Evaluating the efficacy and safety of first-line immunotherapy for metastatic triple-negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials with a focus on PD-L1 expression.Frontiers in oncology · 2026Pooled it
- Efficacy and safety of ivonescimab in non-small cell lung cancer: a systematic review and meta-analysis of emerging clinical data.Frontiers in pharmacology · 2026Pooled it
- Liposomal mitoxantrone plus tislelizumab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma: a phase 1b/2 trial.Nature communications · 2026Trial
- Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study.Nature communications · 2026Trial
- Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma.Journal for immunotherapy of cancer · 2026Trial
- Functionalized biomaterial platforms for interventional embolization therapy of hepatocellular carcinoma.Bioactive materials · 2027Review
- Nanoadjuvant-based membrane poration boosts antitumor immunity via modulating mitochondrial metabolism to downregulate PD-L1 and upregulate STING.Bioactive materials · 2027Article
- Nanocarrier-mediated targeting of chemotherapy-induced DPP4 enhances T cell infiltration and improves cancer immunochemotherapy.Bioactive materials · 2027Article
- PARP7 inhibition and a STING agonist potentiate radiation-induced immunogenicity in glioblastoma.Oncoimmunology · 2026Article
- Hydrogel-Based intraperitoneal drug delivery platforms for peritoneal metastasis: strategies, advances, and prospects.Drug delivery · 2026Review
- PD-1 genetic fate mapping uncovers immune cell diversity mediating the efficacy of combined PD-1 blockade and chemotherapy.Oncoimmunology · 2026Article
- Emerging copper-based hollow nanoplatforms for cancer treatment.International journal of pharmaceutics: X · 2026Review
- Metastatic Urachal Carcinoma With Microsatellite Stability and Low Tumor Mutational Burden Achieving a Durable Response to Pembrolizumab After Platinum Failure.IJU case reports · 2026Article
- Lyophilized bacteria-infected tumor cells for targeted immunotherapy of lung metastases and associated fibrosis.Bioactive materials · 2026Article
1,579 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunogenicity depends on two key factors: antigenicity and adjuvanticity. The presence of exogenous or mutated antigens explains why infected cells and malignant cells can initiate an adaptive immune response provided that the cells also emit adjuvant signals as a consequence of cellular stress and death. Several infectious pathogens have devised strategies to control cell death and limit the emission of danger signals from dying cells, thereby avoiding immune recognition. Similarly, cancer cells often escape immunosurveillance owing to defects in the molecular machinery that underlies the release of endogenous adjuvants. Here, we review current knowledge on the mechanisms that underlie the activation of immune responses against dying cells and their pathophysiological relevance.
Indexed as
Identifiers
27748397What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.